Use of traditional Chinese medicinal compositions in preparation of medicines for treating angina pectoris (syndrome of blood stasis due to deficiency) due to coronary heart disease

Abstract

The invention relates to the use of Chinese medicinal compositions in the preparation of medicines for treating angina pectoris (syndrome of blood stasis due to deficiency) due to coronary heart disease. One Chinese medicinal composition is prepared from the following raw material medicines in part by weight: 20 to 40 parts of astragalus, 2 to 4 parts of scorpio and 4 to 8 parts of centipede. The Chinese medicinal composition has obvious treatment effect on angina pectoris (syndrome of blood stasis due to deficiency) due to coronary heart disease and can reinforce protection of blood vessels. The invention also relates to another Chinese medicinal composition for treating angina pectoris (syndrome of blood stasis due to deficiency) due to coronary heart disease, which also comprises 30 to 60 parts of root of red-rooted salvia, 5 to 25 parts of bitter orange and 9 to 15 parts of peach kernel besides 20 to 40 parts of astragalus, 2 to 4 parts of scorpio and 4 to 8 parts of centipede. Starting from mechanism of the disease, the Chinese medicinal compositions conduct qi-tonifying, blood-activating, qi-regulating and channel-clearing functions to relieve the clinic symptoms and syndromes in traditional Chinese medicine in patients, prevent angina pectoris from breaking out, prevent acute myocardial infarction, reduce cardiovascular events and prevent toxic and side effects; and the raw materials are rich, the preparation process is simple, and the method is suitable to be widely used.

Description

technical field [0001] The invention relates to the use of a traditional Chinese medicine composition, in particular to the application of a traditional Chinese medicine composition in the preparation of medicines for treating coronary heart disease and angina pectoris with Qi deficiency and blood stasis syndrome. Background technique [0002] Coronary atherosclerotic heart disease (CHD) refers to the formation of atherosclerosis in coronary arteries under the action of various risk factors such as hyperlipidemia, hypertension, smoking, diabetes, poor eating habits and lack of exercise. Focus, block the vascular lumen, lead to myocardial ischemia, heart disease caused by hypoxia, also known as ischemic heart disease. In western countries, the death toll caused by coronary heart disease accounts for about 1 / 3 of the total death population. In my country, with the continuous improvement of people's living standards, the morbidity and mortality of coronary heart disease are al...

AI Technical Summary

Problems solved by technology

For example, the Chinese patent document CN 200810194977.6, published on June 9, 2010, discloses a medicine for treating angina pectoris. %, Xuanhu 5-20%, Sandalwood 5-15%, Dalbergia 5-15%, Angelica 5-15%, Pinellia 5-15%, and the drug did not give a clear efficacy experiment, the therapeutic effect Inaccurate; Chinese patent document CN 200910074160.X, announced on May 11, 2011, discloses a Chinese medicine preparation for treating angina pectoris. 30-80 parts, Pueraria 30-80 parts, Schisandra 20-70 parts, Danshen 30-80 parts, Codonopsis 20-90 parts, Wangbuliuxing 20-70 parts, Wulingzhi 20-70 parts, Ophiopogon japonicus 20- 70 parts, Jiangzhenxiang 20-70 parts and Gualou 20-80 parts, but the drug has too many raw materials and the preparation process is relatively complicated

Moreover, the above two types of drugs are not very specific in the treatment of coronary heart disease, angina pectoris, Qi deficiency and blood stasis.

Therefore, there is an urgent need for a medicine with fewer medicinal flavors, low price, simple preparation process, obvious effect in treating angina pectoris of coronary heart disease, and strong pertinence. At present, there are no reports about this class of medicines.

Images